5Suppliers
4Customers
1Debt Items
20Related Chains

Stoke Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
NWALP-PHOP-PROPERTY-OWNER-LLC NWALP-PHOP-PROPERTY-OWNER-LLC 92% On January 21, 2026, Stoke Therapeutics, Inc. (the "Company") entered into a new lease for its corporate headquarters and laboratory with NWALP PHOP Property Owner LLC
ACAD ACADIA Pharmaceuticals Inc. 72% ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional internal manufacturing capabilities in the future if there is a technical need, or a…
ACAD ACADIA Pharmaceuticals Inc. 72% Reciprocal relationship from ACAD graph: Reciprocal relationship from STOK graph: ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional in…
ORANY ORANY 72% ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional internal manufacturing capabilities in the future if there is a technical need, or a…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from STOK graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from STOK graph: ntinue to expand and strengthen o…

Stoke Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
ACAD ACADIA Pharmaceuticals Inc. 72% ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional internal manufacturing capabilities in the future if there is a technical need, or a…
ACAD ACADIA Pharmaceuticals Inc. 72% Reciprocal relationship from ACAD graph: Reciprocal relationship from STOK graph: Reciprocal relationship from ACAD graph: Reciprocal relationship from STOK graph: Reciprocal relationship from ACAD g…
ORANY ORANY 72% ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional internal manufacturing capabilities in the future if there is a technical need, or a…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from STOK graph: ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional i…

Stoke Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
STOK-DEBT Debt stack $3.4M 90% Market cache reports total debt of $3.4M.

Stoke Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Stoke Therapeutics, Inc..

Stoke Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
STOK-OWNER-MORGAN-STANLEY MORGAN STANLEY 90% 13F overlay lists MORGAN STANLEY as top holder; 198 tracked holders.

Stoke Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ATYR aTyr Pharma, Inc. 100.00 2
GH Guardant Health, Inc. 100.00 2
TECX Tectonic Therapeutic, Inc. 100.00 2
ELVN Enliven Therapeutics, Inc. 100.00 2
IMNM Immunome, Inc. 100.00 2
TPST Tempest Therapeutics, Inc. 100.00 2
ORANY ORANGE 100.00 1 ['customer', 'supplier']
SDGR Schrödinger, Inc. 100.00 2
BNBX BNB Plus Corp. 100.00 2
CABA Cabaletta Bio, Inc. 100.00 2
BIAF bioAffinity Technologies, Inc. 100.00 2
GHRS GH Research PLC 100.00 2
HOWL Werewolf Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
BNTC Benitec Biopharma Inc. 100.00 2
CALC CalciMedica, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
PSNL Personalis, Inc. 100.00 2
TEM Tempus AI, Inc. 100.00 2